Clinical Trial

Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China. The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-15.
Trial Details
NCT Number NCT07601516
Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC
Conditions Huntington's Disease, Chorea
Enrollment 50 participants
Start Date 2024-02-02
Primary Completion 2025-10-24 (estimated)
Study Completion 2025-10-24 (estimated)
Updated on ClinicalTrials.gov 2026-06-09